We are grateful to Drs. Scarlata and Antonelli-Incalzi (1) for their interest in our recent publication in Diabetes Care (2) . We respectfully have to disagree with their statement that our study focused on "how rapid eye movement (REM) sleep deprivation due to obstructive sleep apnea [OSA] affects glycemic control in type 2 diabetes." Indeed, our study was a cross-sectional analysis and did not include an experimental paradigm of REM sleep deprivation. In fact, the median duration of REM sleep in our cohort was 20.3% of the total sleep timedwell within the normal range (Supplementary Table 1 in ref. 2). The primary aim of our study was to estimate the impact of OSA in REM sleep and in non-REM sleep on glycemic control (as assessed by HbA 1c ) in patients with type 2 diabetes. In addition, we simulated the impact of different durations of nocturnal CPAP therapy on HbA 1c and observed that longer durations of CPAP use treat more apneas and hypopneas during REM sleep and lead to better glycemic control. We explicitly specified that our simulations were based on the assumption of "optimally titrated CPAP use." Scarlata and Antonelli-Incalzi point out that this assumption may not be met under real-life conditions. Suboptimal CPAP adherence is common and is indeed a likely reason for the negative findings of the only randomized controlled trial of CPAP in type 2 diabetic patients with OSA (3). We also agree with Scarlata and Antonelli-Incalzi that in some instances CPAP may not effectively treat OSA despite adequate adherence. This may be due to an inadequate pressure setting, excessive mask leak, ventilatory instability, and/or emergence of central apneas due to CPAP. However, as reported by Mulgrew et al. (4) , most of the residual respiratory events observed during a full-night polysomnogram on effective CPAP settings are hypopneas and central apneas that occur predominantly during non-REM sleep. Our study demonstrated that in contrast to respiratory events in REM sleep, events during non-REM sleep (i.e., apneas, hypopneas, microarousals, and oxygen desaturations) are not associated with glycemic control in patients with type 2 diabetes. Therefore, simulations that would take into account residual events occurring mostly in non-REM sleep would most likely lead to conclusions similar to those reached in our analysis.
Our model was constructed on the assumption that CPAP is initiated at the beginning of the sleep period. Scarlata and Antonelli-Incalzi share their anecdotal experience that some of their patients start using CPAP in the middle of the night after an awakening. They incorrectly quote the official statement of the American Thoracic Society on CPAP adherence tracking systems as a reference to support this anecdotal evidence (5) . Currently, we are not aware of published empirical data documenting the proportion of OSA patients who start the night on CPAP and then discontinue it after a few hours of treatment as compared with those who initiate CPAP in the middle of the night after an awakening. For what it is worth, our own anecdotal experience suggests that the vast majority of patients with OSA start the night on CPAP and then remove it after a few hours. This constructive comment by Scarlata and Antonelli-Incalzi (1) illuminates the need for a quantitative study of the modalities of CPAP use under real-life conditions and for intervention studies comparing cognitive and cardiometabolic outcomes following early versus late use of CPAP during the night.
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